Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + AVD in Early-Stage Hodgkin's Lymphoma
NCT05900765Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab in classical Hodgkin lymphoma (cHL), sponsored by Sun Yat-sen University. Started Jun 2023; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05900765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900765.